PHOENIX DDR-Anti-PD-L1 Trial

Collection of samples and data across the following diseases: Malignant tumour of breast. PHOENIX DDR/Anti-PD-L1 Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemotherapy resistant residual triple negative breast cancer.

Webpage:
https://www.healthdatagateway.org/dataset/f9c40294-92d8-45cd-b11a-70eb0fc09004

Licence:
Name: HDR UK Innovation Gateway Access
URL: https://www.hdruk.ac.uk/infrastructure/gateway/terms-and-conditions/

Tags:

phoenix ddr anti-pd-l1 trial malignant tumour of breast

More to explore:

1/20

Previous Next   



Need help integrating and/or managing biomedical data?